Cancer is widely recognized as one of the most devastating
diseases,
necessitating the development of intelligent diagnostic techniques,
targeted treatments, and early prognosis evaluation to ensure effective
and personalized therapy. Conventional treatments, unfortunately,
suffer from limitations and an increased risk of severe complications.
In light of these challenges, boron neutron capture therapy (BNCT)
has emerged as a promising approach for cancer treatment with unprecedented
precision to selectively eliminate tumor cells. The distinctive and
promising characteristics of BNCT hold the potential to revolutionize
the field of oncology. However, the clinical application and advancement
of BNCT technology face significant hindrance due to the inherent
flaws and limited availability of current clinical drugs, which pose
substantial obstacles to the practical implementation and continued
progress of BNCT. Consequently, there is an urgent need to develop
efficient boron agents with higher boron content and specific tumor-targeting
properties. Researchers aim to address this need by integrating tumor-targeting
strategies with BNCT, with the ultimate goal of establishing BNCT
as an effective, readily available, and cutting-edge treatment modality
for cancer. This review delves into the recent advancements in integrating
tumor-targeting strategies with BNCT, focusing on the progress made
in developing boron agents specifically designed for BNCT. By exploring
the current state of BNCT and emphasizing the prospects of tumor-targeting
boron agents, this review provides a comprehensive overview of the
advancements in BNCT and highlights its potential as a transformative
treatment option for cancer.